Neurocrine Biosciences Inc. (NBIX) Stock
Key stats
- Market cap
- $17.65B
- Price / Earnings ratio
- 24.4x
- EPS (TTM)
- $6.97
- Volume
- Loading
- 52-week high
- $186.12
- 52-week low
- $122.14
Source: third-party data provider, as of November 13, 2026
Compare with NBIX
Recent news

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
NBIX

Neurocrine Biosciences Q3 Earnings Call Highlights
Neurocrine Biosciences Q3 Earnings Call Highlights
NBIX

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
NBIX

Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say
Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say
NBIX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 75.77
- MACD 12/26/9
- 6.87
- EMA 9 of MACD
- 3.86
- MACD histogram
- 3.01
- SMA 50
- $148.17
- Price above SMA 50
- EMA 50
- $151.71
- Price above EMA 50
- SMA 200
- $148.56
- Price above SMA 200
- EMA 200
- $147.82
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.86 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
NBIX

Neurocrine Biosciences Q3 Earnings Call Highlights
Neurocrine Biosciences Q3 Earnings Call Highlights
NBIX

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
NBIX

Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say
Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say
NBIX

Here's Why Neurocrine Biosciences (NBIX) is a Strong Value Stock
Here's Why Neurocrine Biosciences (NBIX) is a Strong Value Stock
NBIX

Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock
Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock
NBIX

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
NBIX

Where Will Neurocrine Biosciences Be in 5 Years?
Where Will Neurocrine Biosciences Be in 5 Years?
NBIX

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
NBIX

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
NBIX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kyle W. Gano Ph.D. | President, CEO & Director | 1973 |
| Mr. Matthew C. Abernethy CPA | Chief Financial Officer | 1980 |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 1964 |
| Mr. Eric S. Benevich | Chief Commercial Officer | 1965 |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer | 1964 |
| Dr. Wylie W. Vale Ph.D. | Co-Founder | 1942 |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder of Neurocrine | 1948 |
| Mr. Aaron Vosburgh | Senior Vice President of Finance & Accounting | — |
| Mr. Lewis Choi | Chief Information Officer | — |
| Mr. Todd Tushla | Vice President of Investor Relations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 75.77
- MACD 12/26/9
- 6.87
- EMA 9 of MACD
- 3.86
- MACD histogram
- 3.01
- SMA 50
- $148.17
- Price above SMA 50
- EMA 50
- $151.71
- Price above EMA 50
- SMA 200
- $148.56
- Price above SMA 200
- EMA 200
- $147.82
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $150.00
- Average
- $206.11
- High
- $253.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.2 | +5.4 | ||||||||||
| 2022 | -10.7 | +13.4 | +2.0 | -5.8 | +2.5 | +5.1 | -5.2 | +13.7 | +0.5 | +7.9 | +6.5 | -5.4 |
| 2023 | -7.6 | -6.5 | -0.0 | +0.2 | -13.9 | +3.4 | +7.8 | +5.3 | +1.7 | -0.8 | +4.5 | +12.5 |
| 2024 | +6.1 | -8.5 | +5.0 | -2.7 | -5.3 | -1.6 | +1.0 | -17.0 | -7.9 | +5.4 | +3.7 | +8.4 |
| 2025 | +10.1 | -20.9 | -3.4 | +0.6 | +15.4 | +0.9 | +0.2 | +8.3 | -1.1 | +4.5 | +7.2 | -6.0 |
| 2026 | -3.2 | -3.9 | -0.5 | -0.7 | +20.1 | +4.7 | -0.6 | -7.3 | -9.5 | +3.8 | +20.0 |



